Sign up for free insights newsletter
05

China Grand Pharmaceutical and Healthcare Holdings Ltd

0512Hong Kong Stock Exchange

Need professional-grade analysis? Visit stockanalysis.com

HK$6.91
-3.36%
End of day
Market Cap

$25.11B

P/E Ratio

12.15

Employees

12,440

Dividend Yield

3.64%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-2.21-1.78-2.03-1.590.690.23-0.68
Calmar-24.78-5.49-3.11-1.660.630.10-2.40
Sharpe-2.21-1.34-1.59-1.180.440.15-0.57
Omega0.000.700.670.781.121.060.87
Martin-42.91-9.30-6.32-3.651.310.16-4.39
Ulcer1.947.268.249.7414.3234.6216.24

China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) Price Performance

China Grand Pharmaceutical and Healthcare Holdings Ltd (0512) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at HKD6.91, down 3.36% from the previous close.

Over the past year, 0512 has traded between a low of HKD5.34 and a high of HKD9.83. The stock has gained 20.7% over this period. It is currently 29.7% below its 52-week high.

China Grand Pharmaceutical and Healthcare Holdings Ltd has a market capitalization of $25.11B, with a price-to-earnings ratio of 12.15 and a dividend yield of 3.64%.

About China Grand Pharmaceutical and Healthcare Holdings Ltd

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.

Company Info

Exchange
Hong Kong Stock Exchange
Currency
HKD
Country
Hong Kong

Financial Metrics

Revenue (TTM)
$11.70B
EBITDA
$2.45B
Profit Margin
17.77%
EPS (TTM)
0.33
Book Value
4.90

Technical Indicators

52 Week High
HK$10.20
52 Week Low
HK$5.19
50 Day MA
HK$7.66
200 Day MA
HK$8.41
Beta
0.85

Valuation

Trailing P/E
12.15
Forward P/E
N/A
Price/Sales
2.15
Price/Book
1.46
Enterprise Value
$27.84B